Dry liquid metals stabilized by silica particles: Synthesis and application in photothermoelectric power generation.

HYPOTHESIS: Gallium-based room-temperature liquid metals (LMs) have unique physicochemical properties; however, their high surface tension, low flowability, and high corrosiveness to other materials limit their advanced processing (including precise shaping) and application. Consequently, LM-rich free-flowing powders, named "dry LMs" that offer the inherent advantages of dry powders, should play a critical role in expanding the application scope of LMs. EXPERIMENTS: A general method of preparing silica-nanoparticle-stabilized LMs in the form of LM-rich powders (>95 wt% LM) is developed. FINDINGS: Dry LMs can be simply prepared by mixing LMs with silica nanoparticles in a planetary centrifugal mixer in the absence of solvents. As a sustainable dry-process route alternative to wet-process routes, this ecofriendly and simple method of dry LM fabrication has several advantages, e.g., high throughput, scalability, and low toxicity owing to the lack of organic dispersion agents and milling media. Moreover, the unique photothermal properties of dry LMs are used for photothermal electric power generation. Thus, dry LMs not only pave the way for the use of LMs in powder form but also provide a new opportunity for expanding their application scope in energy conversion systems.

A liquid metal catalyst for the conversion of ethanol into graphitic carbon layers under an ultrasonic cavitation field.

Eutectic gallium indium (EGaIn) has drawn considerable research interest in potential liquid catalysis. Herein, we report that EGaIn liquid metal acts as a catalyst for the growth of a graphitic carbon layer from ethanol under ultrasonication. High-speed imaging demonstrated the formation of ultrasonic cavitation bubbles at the liquid metal/ethanol interface, which facilitated the pyrolysis of ethanol into graphitic carbon on the liquid metal surface.

Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions.

Esafoxolaner is a purified afoxolaner enantiomer with insecticidal and acaricidal properties. It is combined with eprinomectin and praziquantel, nematodicidal and cestodicidal compounds, in a novel topical endectoparasiticide formulation for cats. This novel formulation was tested in four field studies, in the United States, Europe, Japan and Australia. In all studies, naturally flea-infested domestic cats were treated with the novel formulation at the label dose and conditions of use. The main objective, identical in the four studies, was to assess efficacy on fleas, based on comparison of mean number of fleas found on infested cats before and one month after treatment. Tolerance to the product was also evaluated in the four studies. Otherwise, the studies had some differences in their design and secondary objectives, for example testing for a reduction in flea infestation-related cutaneous signs, testing of one treatment or of three monthly treatments, and use of a positive control group. In the four studies, a total of 307 cats were treated with the novel formulation. The reduction of fleas one month after treatment was 97.7%, 98.8%, 100% and 99.7% in the United States, Europe, Japan and Australia, respectively. There were no significant health abnormalities attributed to treatment in any of the studies.

TITLE: Efficacité d'une nouvelle association topique d'esafoxolaner, d'éprinomectine et de praziquantel contre les puces chez les chats, dans des conditions de terrain. ABSTRACT: L'esafoxolaner est un énantiomère d'afoxolaner purifié aux propriétés insecticides et acaricides, et il est associé à l'éprinomectine et au praziquantel, des composés nématodicides et cestodicides, dans une nouvelle formulation d'endectoparasiticide topique pour chats. Cette nouvelle formulation a été testée dans quatre études sur le terrain, aux États-Unis, en Europe, au Japon et en Australie. Dans toutes les études, des chats domestiques naturellement infestés de puces ont été traités avec la nouvelle formulation à la dose et aux conditions d'utilisation indiquées sur l'étiquette. L'objectif principal, identique dans les quatre études, était d'évaluer l'efficacité contre les puces, sur la base de la comparaison du nombre moyen de puces trouvées sur des chats infestés avant et un mois après le traitement. La tolérance à l'application du produit a également été évaluée dans les quatre études. Sinon, les études présentaient des différences dans leur conception et leurs objectifs secondaires, par exemple test de réduction des signes cutanés liés à l'infestation par les puces, test d'un traitement ou de trois traitements mensuels, utilisation d'un groupe témoin positif. Dans les quatre études, un total de 307 chats ont été traités avec la nouvelle formulation. La réduction du nombre de puces un mois après le traitement était de 97,7 %, 98,8 %, 100 % et 99,7 % aux États-Unis, en Europe, au Japon et en Australie, respectivement. Aucune anomalie de santé significative n'a été attribuée au traitement dans aucune des études.

Efficacy and safety of firocoxib for the treatment of pain associated with soft tissue surgery in dogs under field conditions in Japan.

Use of firocoxib in dogs for postoperative pain control has not been published in any of the journals in Japan. A field study was conducted to evaluate the efficacy and safety of firocoxib in dogs in controlling pain associated with soft tissue surgery in Japan. The study followed a negative control, double-blind, multicenter clinical efficacy study using a randomized block design. A total of 131 client-owned dogs presented to the clinical practices for soft tissue surgery were enrolled. Sixty-nine dogs were allocated to the firocoxib-treated group and received 5 mg/kg of firocoxib orally on Day 0 before the surgery and once daily through Day 2, while 62 dogs were allocated to the non-treated group handled in a similar manner only without the firocoxib administration. Pain assessment took place on Day 0 before the surgery through Day 2. The primary efficacy variable was a success/failure variable based on whether the dog needed rescue medication (based on pain assessment after the surgery or Investigator's judgment) and a significant difference between firocoxib-treated group (16.4%) and non-treated group (50.0%) (P=0.0031) was observed. There was no adverse event during the study that was considered to be related to the administration of firocoxib. This study indicated the clinical efficacy and safety profile of firocoxib administered to control pain associated with soft tissue surgery under field condition.